Trial reportHaematologica2016
Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study.
Trial report in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Pooled it
- Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.Annals of hematology · 2019Trial
- Melphalan 140 mg/mHaematologica · 2018Trial
- The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.Haematologica · 2026Article
- Reduced-versus Standard-dose Melphalan as Single-agent Conditioning Regimen in Auto HSCT for Multiple Myeloma: A Systematic Review and Meta-Analysis.Blood cell therapy · 2025Article
- Autologous stem cell transplantation in patients older than 65 years with multiple myeloma: a real-world study.Hematology, transfusion and cell therapy · 2024Article
- Outcomes of melphalan 140 mg/mEJHaem · 2024Article
- Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation.Annals of hematology · 2024Article
- Therapeutic Approaches to Increase the Survival Rate of Cancer Patients in the Younger and Older Population.Current aging science · 2024Review
- The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning.Journal of hematology · 2023Article
- Clinical significance of high-dose chemotherapy with autologous stem cell transplantation in the era of novel agents in patients older than 65 years with multiple myeloma.Annals of hematology · 2023Article
- Association of CD 34 positive cell dose with engraftment kinetics in autologous peripheral blood stem cell transplant patients of multiple myeloma.Medical journal, Armed Forces India · 2022Article
- Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study).Frontiers in oncology · 2022Article
- Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma.Haematologica · 2021Article
- Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/mCancer cell international · 2021Review
- Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR).Bone marrow transplantation · 2021Article
- The influence of high-efficiency particulate air filtration on mortality among multiple myeloma patients receiving autologous stem cell transplantation.Scientific reports · 2021Article
- Melphalan 200 mg/mBone marrow transplantation · 2021Article
- The impact of response kinetics for multiple myeloma in the era of novel agents.Blood advances · 2019Review
- Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents.Bone marrow transplantation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The feasibility and efficacy of high-dose melphalan followed by autologous hematopoietic stem cell transplantation in newly diagnosed elderly patients with multiple myeloma was analyzed prospectively. Fifty-six multiple myeloma patients, aged 65 years or over, from 6 French centers were studied. The induction therapy was bortezomib-based in combination with dexamethasone and either thalidomide, cyclophosphamide or lenalidomide, for 4-6 cycles. Peripheral blood stem cells were collected after high-dose cyclophosphamide plus G-CSF or G-CSF alone, with plerixafor if needed. The conditioning regimen consisted of melphalan at 140 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.